Emerging Healthcare enters option agreement with OceanBASIS

Jan 12 2011

Emerging Healthcare Solutions, Inc. announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

“OceanBASIS is working on the cutting edge of regenerative medicine, and we look forward to negotiating a definitive agreement with them soon”

During the 60-day option period, EHSI will conduct a due-diligence review of OceanBASIS and its prospects in order to negotiate a potential profit-sharing agreement. OceanBASIS is a biotech firm dedicated to developing and marketing sustainably derived marine natural products for the health and cosmetic industries. The company's top projects under development include a bone scaffold designed for use as a stem cell matrix in cartilage repairing surgeries and a wound gel intended to improve healing of chronic wounds. Both products are derived from marine collagen, a purer form than the bovine collagen currently being used.

"OceanBASIS is working on the cutting edge of regenerative medicine, and we look forward to negotiating a definitive agreement with them soon," said EHSI President and CEO Cindy Morrissey.

The burgeoning relationship between Emerging Healthcare Solutions and OceanBASIS is a result of EHSI's recent efforts to expand its global reach, including the establishment of a business office in Frankfurt, Germany, in November that will allow EHSI to maintain long-term relationships with some of the world's foremost stem cell researchers in Central and Western Europe.

Emerging Healthcare Solutions keeps a close eye on healthcare innovation worldwide, particularly in relation to stem cells. Last month, EHSI announced its acquisition of Panamanian biotech firm Celulas Genetica, a Central American leader in stem-cell technology acquisition and development. The company subsequently announced that Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease licensed from the Chinese firm BBFITCL.

The Rutherford Procedure is being developed to use proton therapy to destroy scar-tissue cells in the liver using high-energy proton beams. As the scar tissue is systematically destroyed by the proton therapy, a catheter will deliver the patient's own cultured stem cells directly to their liver through the bloodstream in the hope of regenerating the damaged, cirrhotic liver into a healthy, functioning organ once more.